Capricor Therapeutics Reports Third Quarter 2019 Financial Results and Provides Recent Corporate Update
07. November 2019 16:00 ET
|
Capricor Therapeutics, Inc.
Provides Update on End of Phase Type-B Meeting with FDA Positive Data from the HOPE-2 Clinical Trial Presented at World Muscle Society To Host Conference Call and Webcast Today at 4:30 p.m....
Capricor Therapeutics Reports Second Quarter 2019 Financial Results and Provides Corporate Update
06. August 2019 16:00 ET
|
Capricor Therapeutics, Inc.
Positive Results from HOPE-2 Interim Analysis Reported in July To Host Conference Call and Webcast Today at 4:30 p.m. ET LOS ANGELES, Aug. 06, 2019 (GLOBE NEWSWIRE) -- Capricor Therapeutics...
Capricor Therapeutics to Present Second Quarter 2019 Financial Results and Recent Corporate Update on August 6
30. Juli 2019 08:00 ET
|
Capricor Therapeutics, Inc.
LOS ANGELES, July 30, 2019 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a clinical-stage biotechnology company focused on the development of first-in-class biological therapeutics for...
Capricor Therapeutics Reports First Quarter 2019 Financial Results and Provides Corporate Update
13. Mai 2019 16:00 ET
|
Capricor Therapeutics, Inc.
On Track to Report Interim Data from HOPE-2 Clinical Trial in Early Q3 To Host Conference Call and Webcast Today at 4:30 p.m. ET LOS ANGELES, May 13, 2019 (GLOBE NEWSWIRE) -- Capricor Therapeutics...
Capricor Therapeutics to Present Fourth Quarter and Full Year 2018 Financial Results and Recent Corporate Update on March 28
21. März 2019 08:00 ET
|
Capricor Therapeutics, Inc.
LOS ANGELES, March 21, 2019 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a clinical-stage biotechnology company focused on the development of first-in-class biological therapeutics for...
Capricor Therapeutics Reports Third Quarter 2018 Financial Results and Provides Corporate Update
13. November 2018 16:01 ET
|
Capricor Therapeutics, Inc.
To Host Conference Call and Webcast Today at 4:30 p.m. ET LOS ANGELES, Nov. 13, 2018 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a clinical-stage biotechnology company focused on the...
Capricor Therapeutics to Participate in Upcoming Conferences
22. Oktober 2018 07:00 ET
|
Capricor Therapeutics, Inc.
Presentations to Focus on Company’s Exosome-based and Duchenne Muscular Dystrophy Therapies LOS ANGELES, Oct. 22, 2018 (GLOBE NEWSWIRE) -- Linda Marbán, Ph.D, CEO of Capricor Therapeutics, Inc....
Capricor Therapeutics to Present at 2018 Cell & Gene Meeting on the Mesa
03. Oktober 2018 07:00 ET
|
Capricor Therapeutics, Inc.
LA JOLLA, Calif., Oct. 03, 2018 (GLOBE NEWSWIRE) -- Capricor Therapeutics, Inc. (NASDAQ: CAPR) will provide a presentation at the 2018 Cell & Gene Meeting on the Mesa today on its cell therapy,...
Capricor Therapeutics Presents Results of Studies of CAP-2003 at Gordon Research Conference on Extracellular Vesicles
21. August 2018 07:00 ET
|
Capricor Therapeutics, Inc.
LOS ANGELES, Aug. 21, 2018 (GLOBE NEWSWIRE) -- At the Gordon Research Conference on Extracellular Vesicles in Newry, Maine, Capricor Therapeutics (NASDAQ: CAPR) presented research findings on the...
Capricor and USAISR Announce Collaboration to Investigate Exosome Platform to Treat Injured Troops
17. Juli 2018 07:00 ET
|
Capricor Therapeutics, Inc.
LOS ANGELES, July 17, 2018 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ:CAPR) today announced it has entered into an agreement with the U.S. Army Institute of Surgical Research (USAISR) to...